Shopping Cart
- Remove All
- Your shopping cart is currently empty
Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cancer activity and can be used to study ossifying fibrous dysplasia (FOP) and cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $328 | In Stock | |
5 mg | $863 | In Stock | |
10 mg | $1,370 | In Stock |
Description | Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cancer activity and can be used to study ossifying fibrous dysplasia (FOP) and cancer. |
In vitro | Specifically binding to and blocking signaling of activin proteins containing the inhibin βα subunit (activins A, AB, and AC), garetosmab (REGN 2477) has high affinity and specificity for activins A, AB, and AC in vitro. It does not bind or functionally inhibit other TGF-β family ligands that share the same activin receptor pathways, including activin B, inhibin A, BMP-2, BMP6, BMP9, BMP10, GDF8, and GDF11[1]. |
Alias | REGN 2477 |
Molecular Weight | 146 kDa |
Cas No. | 2097125-54-5 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.